Oddo BHF Asset Management Sas Invests $10.70 Million in Abivax SA Sponsored ADR $ABVX

Oddo BHF Asset Management Sas bought a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 79,350 shares of the company’s stock, valued at approximately $10,701,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ABVX. UBS Group AG raised its position in shares of Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after acquiring an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of Abivax during the 3rd quarter worth about $263,698,000. Morgan Stanley raised its position in shares of Abivax by 114.3% during the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock worth $425,062,000 after acquiring an additional 1,681,277 shares in the last quarter. Paradigm Biocapital Advisors LP acquired a new stake in shares of Abivax during the 3rd quarter worth about $132,800,000. Finally, TCG Crossover Management LLC raised its position in shares of Abivax by 17.4% during the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after acquiring an additional 1,055,000 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Wall Street Analysts Forecast Growth

ABVX has been the topic of several research analyst reports. BTIG Research reaffirmed a “buy” rating and set a $150.00 price target on shares of Abivax in a research report on Tuesday. Morgan Stanley cut their price target on Abivax from $145.00 to $132.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Jefferies Financial Group lowered Abivax from a “buy” rating to a “hold” rating and cut their price target for the stock from $160.00 to $90.00 in a research report on Tuesday, June 2nd. Finally, Truist Financial cut their price target on Abivax from $140.00 to $135.00 and set a “buy” rating on the stock in a research report on Tuesday, June 2nd. Twelve equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $130.08.

Abivax Trading Up 1.8%

NASDAQ:ABVX opened at $98.26 on Tuesday. The firm has a market cap of $7.84 billion, a P/E ratio of -18.86 and a beta of 0.69. The stock’s 50 day simple moving average is $115.61 and its 200-day simple moving average is $118.86. Abivax SA Sponsored ADR has a 12-month low of $5.69 and a 12-month high of $148.83.

Abivax (NASDAQ:ABVX) last released its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. Research analysts forecast that Abivax SA Sponsored ADR will post -3.4 EPS for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.